PC
CLDX icon

PointState Capital’s Celldex Therapeutics CLDX Stock Holding History

PointState Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-13,333
Closed -$5.57M – 158
2015
Q1 		$5.57M Buy
+13,333
New +$4.77M 0.08% 94

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PointState Capital's CLDX Position: Q2 2015 in Review

PointState Capital sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 13,333 shares — an estimated $5.57M sold.

PointState Capital first reported a position in CLDX in Q1 2015 and held it in 1 quarter. The position peaked at $5.57M in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • PointState Capital reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • PointState Capital sold 13,333 Celldex Therapeutics shares in Q2 2015, an estimated $5.57M.
  • PointState Capital first reported a position in Celldex Therapeutics in Q1 2015 and held it in 1 quarter.
  • PointState Capital's Celldex Therapeutics position peaked at $5.57M in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on PointState Capital's 13F filing for Q2 2015, filed 14 Aug 2015.